NEW YORK (GenomeWeb News) – Investment bank JPMorgan has initiated coverage of Illumina with an “Overweight” rating on the firm’s stock.
 
JPMorgan analyst Tycho Peterson said in a lengthy research note published today that Illumina is “one of the best positioned [companies] to capitalize on a growing market for genetic analysis tools, including products for genotyping gene expression, next-generation DNA sequencing, molecular diagnostics, and for the applied and consumer markets.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.